We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Steroid Injection Treatment of Carpal Tunnel Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00806871
Recruitment Status : Completed
First Posted : December 11, 2008
Last Update Posted : April 4, 2012
Information provided by (Responsible Party):
Region Skane

December 10, 2008
December 11, 2008
April 4, 2012
November 2008
April 2012   (Final data collection date for primary outcome measure)
  • The CTS symptom severity score after treatment. [ Time Frame: 10 weeks ]
  • Rate of surgery [ Time Frame: 52 weeks ]
Same as current
Complete list of historical versions of study NCT00806871 on ClinicalTrials.gov Archive Site
  • The CTS symptom severity score after treatment [ Time Frame: 52 weeks ]
  • Time to surgery [ Time Frame: 52 weeks ]
  • QuickDASH score [ Time Frame: 52 weeks ]
  • SF-6D score [ Time Frame: 52 weeks ]
  • Patient satisfaction with the results of treatment (VAS scale) [ Time Frame: 52 weeks ]
  • Registration of adverse events [ Time Frame: 24 weeks ]
Same as current
Not Provided
Not Provided
Steroid Injection Treatment of Carpal Tunnel Syndrome
Local Steroid Injection in the Treatment of Idiopathic Carpal Tunnel Syndrome: A Randomized Double-blind Placebo-controlled Trial Among Patients Planned for Surgical Treatment
The aim of this study is to assess the efficacy of injecting steroid into the carpal tunnel in relieving symptoms of carpal tunnel syndrome for at least 1 year with outcomes measured with patient evaluated symptoms score.Out of the patients referred by primary care, those with a clinical diagnosis of CTS who have tried wrist splint and whose symptom severity is judged by the examining surgeon to warrant surgery are offered to be put on the waiting list for carpal tunnel release. This means a waiting time of approximately 3 months. Patients who give informed consent will be asked to attend the outpatient clinic for a physical examination followed by allocation to one of the three trial groups. Immediately following the allocation the patients will receive the assigned treatment.
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Carpal Tunnel Syndrome
  • Drug: Methylprednisolone 40 mg

    Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use

    1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline

    Other Name: Depo-medrol
  • Drug: Methylprednisolone 80 mg

    Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.

    2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine

    Other Name: Depo-medrol
  • Drug: Sodium chloride

    Saline solution 0,9%, injection in the carpal tunnel, one time use

    1 ml 10 mg Lidocaine + 2 ml saline

    Other Names:
    • Saline
    • NaCl
  • Active Comparator: A
    Intervention: Drug: Methylprednisolone 40 mg
  • Active Comparator: B
    Intervention: Drug: Methylprednisolone 80 mg
  • Placebo Comparator: C
    Intervention: Drug: Sodium chloride

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
April 2012
April 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Primary, idiopathic CTS
  • Age 18-70 years, either gender
  • Symptom duration of at least 3 months and inadequate response to wrist splint
  • Symptoms of classic or probable CTS according to the diagnostic criteria in Katz hand diagram
  • Nerve conduction studies showing median neuropathy at the wrist and no other abnormalities or, in the absence of abnormal nerve conduction study results, 2 surgeons should independently diagnose the patient with CTS.
  • Scheduled for carpal tunnel release (ie, symptom severity indicating need for surgery)exclusion criteria

Exclusion Criteria:

  • Previous steroid injection for CTS in the same wrist
  • Inflammatory joint disease, diabetes mellitus· Vibration-induced neuropathy, polyneuropathy
  • Pregnancy
  • Trauma to the affected hand in the previous year
  • Previous CTS surgery in the affected hand
  • Inability to complete questionnaires due to language problem or cognitive disorder
  • Severe medical illness
  • Known abuse of drugs and/or alcohol
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
prövningsprotokoll 080723
Not Provided
Not Provided
Region Skane
Region Skane
Not Provided
Study Chair: Isam Atroshi, MD, PhD Lund university, department of clinical sciences, Hässleholm hospital, department of orthopedics
Region Skane
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP